Omicron Tailored Covid 19 Vaccines Could Updated Shots Prevent A Wave Of Decline National

A bivalent vaccine targets two different variants of the same virus. The new vaccines are still awaiting approval in Canada and while there is no word on when they will land, Canadian doctors are optimistic about a possible launch.

		Read more: 1st vaccine adapted to a COVID-19 variant approved in the UK 		

“These updated vaccines are an amazing tool, but the real game changer will be delivery,” said Dr. Omar Khan, a professor of biomedical engineering and immunology at the University of Toronto. “As long as we can get it to as many people as possible around the world, that’s really what’s going to slow down the progression of the virus and prevent a new variant,” he told Global News. Story continues below ad On Monday, the UK became the first country to approve Moderna’s so-called bivalent vaccine as a booster for adults. Both Pfizer and Moderna have submitted applications to Health Canada for bivalent vaccines targeting the original variant of the virus and the Omicron BA.1 subline. Those submissions are currently under review, Health Canada spokesman Mark Johnson told Global News on Monday. “As with all COVID-19 vaccine submissions, these are being reviewed on a priority basis by dedicated scientific teams,” he said in an email. 1:43 Who should take the second booster shot? Who should get the second booster shot? – July 30, 2022 In Canada, daily cases of COVID-19 are declining, but public health officials and other experts have warned that infections could rise again in the fall as activities move indoors. Story continues below ad That’s why the National Advisory Committee on Immunization (NACI) recommended booster shots this fall before a possible future wave of COVID-19.

			Will updated vaccines protect against new variants?			 

Currently, the adult population can be boosted with COVID-19 doses that target the original variant of the virus. Bivalent vaccines have been updated to include the Omicron BA.1 subvariant – but not BA.5, which is currently predominant in Canada and worldwide. Because of this, Dr. Jun Liu, an infectious disease expert at the University of Toronto and a researcher for the COVID-19 Immunity Task Force, isn’t sure the new vaccines will have a significant impact on preventing a wave of falls. “Ideally, I think adding the BA.5 variant would be best to deal with any direct surge in the fall,” he said. Story continues below ad Almost half of Canada’s total population has been boosted with a third dose and about 10 percent have received a fourth dose.

		Read more: COVID-19 — How bivalent vaccines could help protect against new variants 		

The US Food and Drug Administration recommended that manufacturers of COVID-19 vaccines change the design of their booster cartridges to include components adapted to combat Omicron’s BA.4 and BA.5 subvariants. Although mRNA vaccines are easy to update, the challenge is testing them in clinical trials to show safety and efficacy, which takes more time, experts say. It’s a “game of cover” as the virus changes very quickly, Liu said. “Basically we are fighting against the virus and unfortunately we always fall behind.” 2:03 Omicron subvariants fuel fears of COVID-19 reinfections Omicron subvariants fuel fears of COVID-19 reinfections – July 12, 2022 In approving Moderna’s bivalent vaccine, the UK medicines regulator said its decision was based on clinical trial data showing the booster triggered a “robust immune response” against both Omicron (BA.1) and the parent virus of 2020. Story continues below ad The Medicines and Healthcare Products Regulatory Agency also reported an exploratory analysis that found the vaccine produced a good immune response against Omicron’s BA.4 and BA.5 offshoots. No serious safety concerns were identified with this new formulation, the agency added.

		Read more: 4th dose of COVID-19 — What’s the value of an extra souvenir? 		

Based on clinical trial data, Pfizer said in June that its Omicron-adapted bivalent vaccine elicited significantly higher neutralizing antibody responses against Omicron BA.1 compared to the current COVID-19 vaccine. Preliminary laboratory studies show that the updated vaccine also neutralized the BA.4 and BA.5 subvariants but to a lesser extent, Pfizer said. Khan hopes the updated vaccines will offer protection against reinfection. “Just like how the original version of the vaccine was impervious to Delta and even to some extent Omicron, we hope to see the same level of persistence in these vaccines,” he said. — with files from Reuters © 2022 Global News, a division of Corus Entertainment Inc.

title: “Omicron Tailored Covid 19 Vaccines Could Updated Shots Prevent A Wave Of Decline National Klmat” ShowToc: true date: “2022-11-27” author: “Joseph Hinton”

A bivalent vaccine targets two different variants of the same virus. The new vaccines are still awaiting approval in Canada and while there is no word on when they will land, Canadian doctors are optimistic about a possible launch.

		Read more: 1st vaccine adapted to a COVID-19 variant approved in the UK 		

“These updated vaccines are an amazing tool, but the real game changer will be delivery,” said Dr. Omar Khan, a professor of biomedical engineering and immunology at the University of Toronto. “As long as we can get it to as many people as possible around the world, that’s really what’s going to slow down the progression of the virus and prevent a new variant,” he told Global News. Story continues below ad On Monday, the UK became the first country to approve Moderna’s so-called bivalent vaccine as a booster for adults. Both Pfizer and Moderna have submitted applications to Health Canada for bivalent vaccines targeting the original variant of the virus and the Omicron BA.1 subline. Those submissions are currently under review, Health Canada spokesman Mark Johnson told Global News on Monday. “As with all COVID-19 vaccine submissions, these are being reviewed on a priority basis by dedicated scientific teams,” he said in an email. 1:43 Who should take the second booster shot? Who should get the second booster shot? – July 30, 2022 In Canada, daily cases of COVID-19 are declining, but public health officials and other experts have warned that infections could rise again in the fall as activities move indoors. Story continues below ad That’s why the National Advisory Committee on Immunization (NACI) recommended booster shots this fall before a possible future wave of COVID-19.

			Will updated vaccines protect against new variants?			 

Currently, the adult population can be boosted with COVID-19 doses that target the original variant of the virus. Bivalent vaccines have been updated to include the Omicron BA.1 subvariant – but not BA.5, which is currently predominant in Canada and worldwide. Because of this, Dr. Jun Liu, an infectious disease expert at the University of Toronto and a researcher for the COVID-19 Immunity Task Force, isn’t sure the new vaccines will have a significant impact on preventing a wave of falls. “Ideally, I think adding the BA.5 variant would be best to deal with any direct surge in the fall,” he said. Story continues below ad Almost half of Canada’s total population has been boosted with a third dose and about 10 percent have received a fourth dose.

		Read more: COVID-19 — How bivalent vaccines could help protect against new variants 		

The US Food and Drug Administration recommended that manufacturers of COVID-19 vaccines change the design of their booster cartridges to include components adapted to combat Omicron’s BA.4 and BA.5 subvariants. Although mRNA vaccines are easy to update, the challenge is testing them in clinical trials to show safety and efficacy, which takes more time, experts say. It’s a “game of cover” as the virus changes very quickly, Liu said. “Basically we are fighting against the virus and unfortunately we always fall behind.” 2:03 Omicron subvariants fuel fears of COVID-19 reinfections Omicron subvariants fuel fears of COVID-19 reinfections – July 12, 2022 In approving Moderna’s bivalent vaccine, the UK medicines regulator said its decision was based on clinical trial data showing the booster triggered a “robust immune response” against both Omicron (BA.1) and the parent virus of 2020. Story continues below ad The Medicines and Healthcare Products Regulatory Agency also reported an exploratory analysis that found the vaccine produced a good immune response against Omicron’s BA.4 and BA.5 offshoots. No serious safety concerns were identified with this new formulation, the agency added.

		Read more: 4th dose of COVID-19 — What’s the value of an extra souvenir? 		

Based on clinical trial data, Pfizer said in June that its Omicron-adapted bivalent vaccine elicited significantly higher neutralizing antibody responses against Omicron BA.1 compared to the current COVID-19 vaccine. Preliminary laboratory studies show that the updated vaccine also neutralized the BA.4 and BA.5 subvariants but to a lesser extent, Pfizer said. Khan hopes the updated vaccines will offer protection against reinfection. “Just like how the original version of the vaccine was impervious to Delta and even to some extent Omicron, we hope to see the same level of persistence in these vaccines,” he said. — with files from Reuters © 2022 Global News, a division of Corus Entertainment Inc.

title: “Omicron Tailored Covid 19 Vaccines Could Updated Shots Prevent A Wave Of Decline National Klmat” ShowToc: true date: “2022-11-03” author: “Lee Baxter”

A bivalent vaccine targets two different variants of the same virus. The new vaccines are still awaiting approval in Canada and while there is no word on when they will land, Canadian doctors are optimistic about a possible launch.

		Read more: 1st vaccine adapted to a COVID-19 variant approved in the UK 		

“These updated vaccines are an amazing tool, but the real game changer will be delivery,” said Dr. Omar Khan, a professor of biomedical engineering and immunology at the University of Toronto. “As long as we can get it to as many people as possible around the world, that’s really what’s going to slow down the progression of the virus and prevent a new variant,” he told Global News. Story continues below ad On Monday, the UK became the first country to approve Moderna’s so-called bivalent vaccine as a booster for adults. Both Pfizer and Moderna have submitted applications to Health Canada for bivalent vaccines targeting the original variant of the virus and the Omicron BA.1 subline. Those submissions are currently under review, Health Canada spokesman Mark Johnson told Global News on Monday. “As with all COVID-19 vaccine submissions, these are being reviewed on a priority basis by dedicated scientific teams,” he said in an email. 1:43 Who should take the second booster shot? Who should get the second booster shot? – July 30, 2022 In Canada, daily cases of COVID-19 are declining, but public health officials and other experts have warned that infections could rise again in the fall as activities move indoors. Story continues below ad That’s why the National Advisory Committee on Immunization (NACI) recommended booster shots this fall before a possible future wave of COVID-19.

			Will updated vaccines protect against new variants?			 

Currently, the adult population can be boosted with COVID-19 doses that target the original variant of the virus. Bivalent vaccines have been updated to include the Omicron BA.1 subvariant – but not BA.5, which is currently predominant in Canada and worldwide. Because of this, Dr. Jun Liu, an infectious disease expert at the University of Toronto and a researcher for the COVID-19 Immunity Task Force, isn’t sure the new vaccines will have a significant impact on preventing a wave of falls. “Ideally, I think adding the BA.5 variant would be best to deal with any direct surge in the fall,” he said. Story continues below ad Almost half of Canada’s total population has been boosted with a third dose and about 10 percent have received a fourth dose.

		Read more: COVID-19 — How bivalent vaccines could help protect against new variants 		

The US Food and Drug Administration recommended that manufacturers of COVID-19 vaccines change the design of their booster cartridges to include components adapted to combat Omicron’s BA.4 and BA.5 subvariants. Although mRNA vaccines are easy to update, the challenge is testing them in clinical trials to show safety and efficacy, which takes more time, experts say. It’s a “game of cover” as the virus changes very quickly, Liu said. “Basically we are fighting against the virus and unfortunately we always fall behind.” 2:03 Omicron subvariants fuel fears of COVID-19 reinfections Omicron subvariants fuel fears of COVID-19 reinfections – July 12, 2022 In approving Moderna’s bivalent vaccine, the UK medicines regulator said its decision was based on clinical trial data showing the booster triggered a “robust immune response” against both Omicron (BA.1) and the parent virus of 2020. Story continues below ad The Medicines and Healthcare Products Regulatory Agency also reported an exploratory analysis that found the vaccine produced a good immune response against Omicron’s BA.4 and BA.5 offshoots. No serious safety concerns were identified with this new formulation, the agency added.

		Read more: 4th dose of COVID-19 — What’s the value of an extra souvenir? 		

Based on clinical trial data, Pfizer said in June that its Omicron-adapted bivalent vaccine elicited significantly higher neutralizing antibody responses against Omicron BA.1 compared to the current COVID-19 vaccine. Preliminary laboratory studies show that the updated vaccine also neutralized the BA.4 and BA.5 subvariants but to a lesser extent, Pfizer said. Khan hopes the updated vaccines will offer protection against reinfection. “Just like how the original version of the vaccine was impervious to Delta and even to some extent Omicron, we hope to see the same level of persistence in these vaccines,” he said. — with files from Reuters © 2022 Global News, a division of Corus Entertainment Inc.

title: “Omicron Tailored Covid 19 Vaccines Could Updated Shots Prevent A Wave Of Decline National Klmat” ShowToc: true date: “2022-12-10” author: “James Upright”

A bivalent vaccine targets two different variants of the same virus. The new vaccines are still awaiting approval in Canada and while there is no word on when they will land, Canadian doctors are optimistic about a possible launch.

		Read more: 1st vaccine adapted to a COVID-19 variant approved in the UK 		

“These updated vaccines are an amazing tool, but the real game changer will be delivery,” said Dr. Omar Khan, a professor of biomedical engineering and immunology at the University of Toronto. “As long as we can get it to as many people as possible around the world, that’s really what’s going to slow down the progression of the virus and prevent a new variant,” he told Global News. Story continues below ad On Monday, the UK became the first country to approve Moderna’s so-called bivalent vaccine as a booster for adults. Both Pfizer and Moderna have submitted applications to Health Canada for bivalent vaccines targeting the original variant of the virus and the Omicron BA.1 subline. Those submissions are currently under review, Health Canada spokesman Mark Johnson told Global News on Monday. “As with all COVID-19 vaccine submissions, these are being reviewed on a priority basis by dedicated scientific teams,” he said in an email. 1:43 Who should take the second booster shot? Who should get the second booster shot? – July 30, 2022 In Canada, daily cases of COVID-19 are declining, but public health officials and other experts have warned that infections could rise again in the fall as activities move indoors. Story continues below ad That’s why the National Advisory Committee on Immunization (NACI) recommended booster shots this fall before a possible future wave of COVID-19.

			Will updated vaccines protect against new variants?			 

Currently, the adult population can be boosted with COVID-19 doses that target the original variant of the virus. Bivalent vaccines have been updated to include the Omicron BA.1 subvariant – but not BA.5, which is currently predominant in Canada and worldwide. Because of this, Dr. Jun Liu, an infectious disease expert at the University of Toronto and a researcher for the COVID-19 Immunity Task Force, isn’t sure the new vaccines will have a significant impact on preventing a wave of falls. “Ideally, I think adding the BA.5 variant would be best to deal with any direct surge in the fall,” he said. Story continues below ad Almost half of Canada’s total population has been boosted with a third dose and about 10 percent have received a fourth dose.

		Read more: COVID-19 — How bivalent vaccines could help protect against new variants 		

The US Food and Drug Administration recommended that manufacturers of COVID-19 vaccines change the design of their booster cartridges to include components adapted to combat Omicron’s BA.4 and BA.5 subvariants. Although mRNA vaccines are easy to update, the challenge is testing them in clinical trials to show safety and efficacy, which takes more time, experts say. It’s a “game of cover” as the virus changes very quickly, Liu said. “Basically we are fighting against the virus and unfortunately we always fall behind.” 2:03 Omicron subvariants fuel fears of COVID-19 reinfections Omicron subvariants fuel fears of COVID-19 reinfections – July 12, 2022 In approving Moderna’s bivalent vaccine, the UK medicines regulator said its decision was based on clinical trial data showing the booster triggered a “robust immune response” against both Omicron (BA.1) and the parent virus of 2020. Story continues below ad The Medicines and Healthcare Products Regulatory Agency also reported an exploratory analysis that found the vaccine produced a good immune response against Omicron’s BA.4 and BA.5 offshoots. No serious safety concerns were identified with this new formulation, the agency added.

		Read more: 4th dose of COVID-19 — What’s the value of an extra souvenir? 		

Based on clinical trial data, Pfizer said in June that its Omicron-adapted bivalent vaccine elicited significantly higher neutralizing antibody responses against Omicron BA.1 compared to the current COVID-19 vaccine. Preliminary laboratory studies show that the updated vaccine also neutralized the BA.4 and BA.5 subvariants but to a lesser extent, Pfizer said. Khan hopes the updated vaccines will offer protection against reinfection. “Just like how the original version of the vaccine was impervious to Delta and even to some extent Omicron, we hope to see the same level of persistence in these vaccines,” he said. — with files from Reuters © 2022 Global News, a division of Corus Entertainment Inc.

title: “Omicron Tailored Covid 19 Vaccines Could Updated Shots Prevent A Wave Of Decline National Klmat” ShowToc: true date: “2022-11-15” author: “Jerry Hicks”

A bivalent vaccine targets two different variants of the same virus. The new vaccines are still awaiting approval in Canada and while there is no word on when they will land, Canadian doctors are optimistic about a possible launch.

		Read more: 1st vaccine adapted to a COVID-19 variant approved in the UK 		

“These updated vaccines are an amazing tool, but the real game changer will be delivery,” said Dr. Omar Khan, a professor of biomedical engineering and immunology at the University of Toronto. “As long as we can get it to as many people as possible around the world, that’s really what’s going to slow down the progression of the virus and prevent a new variant,” he told Global News. Story continues below ad On Monday, the UK became the first country to approve Moderna’s so-called bivalent vaccine as a booster for adults. Both Pfizer and Moderna have submitted applications to Health Canada for bivalent vaccines targeting the original variant of the virus and the Omicron BA.1 subline. Those submissions are currently under review, Health Canada spokesman Mark Johnson told Global News on Monday. “As with all COVID-19 vaccine submissions, these are being reviewed on a priority basis by dedicated scientific teams,” he said in an email. 1:43 Who should take the second booster shot? Who should get the second booster shot? – July 30, 2022 In Canada, daily cases of COVID-19 are declining, but public health officials and other experts have warned that infections could rise again in the fall as activities move indoors. Story continues below ad That’s why the National Advisory Committee on Immunization (NACI) recommended booster shots this fall before a possible future wave of COVID-19.

			Will updated vaccines protect against new variants?			 

Currently, the adult population can be boosted with COVID-19 doses that target the original variant of the virus. Bivalent vaccines have been updated to include the Omicron BA.1 subvariant – but not BA.5, which is currently predominant in Canada and worldwide. Because of this, Dr. Jun Liu, an infectious disease expert at the University of Toronto and a researcher for the COVID-19 Immunity Task Force, isn’t sure the new vaccines will have a significant impact on preventing a wave of falls. “Ideally, I think adding the BA.5 variant would be best to deal with any direct surge in the fall,” he said. Story continues below ad Almost half of Canada’s total population has been boosted with a third dose and about 10 percent have received a fourth dose.

		Read more: COVID-19 — How bivalent vaccines could help protect against new variants 		

The US Food and Drug Administration recommended that manufacturers of COVID-19 vaccines change the design of their booster cartridges to include components adapted to combat Omicron’s BA.4 and BA.5 subvariants. Although mRNA vaccines are easy to update, the challenge is testing them in clinical trials to show safety and efficacy, which takes more time, experts say. It’s a “game of cover” as the virus changes very quickly, Liu said. “Basically we are fighting against the virus and unfortunately we always fall behind.” 2:03 Omicron subvariants fuel fears of COVID-19 reinfections Omicron subvariants fuel fears of COVID-19 reinfections – July 12, 2022 In approving Moderna’s bivalent vaccine, the UK medicines regulator said its decision was based on clinical trial data showing the booster triggered a “robust immune response” against both Omicron (BA.1) and the parent virus of 2020. Story continues below ad The Medicines and Healthcare Products Regulatory Agency also reported an exploratory analysis that found the vaccine produced a good immune response against Omicron’s BA.4 and BA.5 offshoots. No serious safety concerns were identified with this new formulation, the agency added.

		Read more: 4th dose of COVID-19 — What’s the value of an extra souvenir? 		

Based on clinical trial data, Pfizer said in June that its Omicron-adapted bivalent vaccine elicited significantly higher neutralizing antibody responses against Omicron BA.1 compared to the current COVID-19 vaccine. Preliminary laboratory studies show that the updated vaccine also neutralized the BA.4 and BA.5 subvariants but to a lesser extent, Pfizer said. Khan hopes the updated vaccines will offer protection against reinfection. “Just like how the original version of the vaccine was impervious to Delta and even to some extent Omicron, we hope to see the same level of persistence in these vaccines,” he said. — with files from Reuters © 2022 Global News, a division of Corus Entertainment Inc.